Syngene International (NSE:SYNGENE) Notes Receivable: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SYNGENE Syngene International Ltd NSE:SYNGENE
81 GF Score
Price ₹406.65
GF Value ₹771.22
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Syngene International Notes Receivable?

Syngene International NSE:SYNGENE +0.84% 81 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SYNGENE with a GF Score™ of 81/100 and a GF Value™ of ₹771.22 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Syngene International's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Syngene International Notes Receivable Related Terms

Syngene International Notes Receivable Historical Data

* Premium members only.

The historical data trend for Syngene International's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syngene International Notes Receivable Chart

Syngene International Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Syngene International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SYNGENE
81GF Score
Syngene International Ltd NSE:SYNGENE
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syngene International Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Syngene International (NSE:SYNGENE) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Syngene International and its competitors.
Is Syngene International's Notes Receivable too high?
Syngene International's current Notes Receivable is ₹0 Mil. Overall, Syngene International has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's Notes Receivable compare to TMO and DHR?
Syngene International's Notes Receivable of ₹0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Syngene International and its competitors. Syngene International's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹771.22, compared to a current price of ₹406.65 — trading 47.3% below its estimated fair value. The current Notes Receivable is ₹0 Mil. Syngene International's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syngene International (NSE:SYNGENE) Overvalued in 2026?

Based on GuruFocus' analysis, Syngene International stock appears to be undervalued. The current stock price of ₹406.65 is trading 47.3% below its estimated GF Value™ of ₹771.22. GuruFocus considers Syngene International to be Significantly Undervalued.

Key valuation signals for NSE:SYNGENE:

  • Notes Receivable: ₹0 Mil
  • GF Value™: ₹771.22 vs. price of ₹406.65 (47.3% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syngene International Business Description

Other Exchanges 539268:India
Address Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
81GF Score

Get the complete analysis for NSE:SYNGENE

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹406.65
Price
₹771.22
GF Value